ARMP vs ARVN

Armata Pharmaceuticals, Inc. vs Arvinas, Inc. — Valuation Comparison 2026

ARMP

Biotechnology
Armata Pharmaceuticals, Inc.
Quality
3.5
out of 10
Value Trap
18
SAFE
Price
$8.12
Last close
Models
7/13
Active
VS

ARVN

Biotechnology
Arvinas, Inc.
Quality
6.9
out of 10
Value Trap
12
SAFE
Price
$8.84
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType ARMP Fair ValueARMP Upside ARVN Fair ValueARVN Upside
Bayesian DCF Intrinsic $1.04 -87.2% $2.43 -72.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.87 -89.5% $1.47 -83.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $15.46 +90.4% $12.09 +36.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARMP vs ARVN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARMP vs ARVN — Which Stock Is More Undervalued?

ARVN scores higher with a 6.9/10 quality rating vs ARMP's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Armata Pharmaceuticals, Inc. (ARMP) and Arvinas, Inc. (ARVN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARMP currently trades at $8.12 with a QOC of 3.5/10, while ARVN trades at $8.84 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).